Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-363856 (ulotaront) metabolic effects in schizophrenia
NCT05463770Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Aug 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ulotaront in schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Area under the concentration-time curve from 0 to 120 minutes of plasma glucose in oral glucose tolerance test, Area under the concentration-time curve from 0 to 120 minutes of plasma insulin in oral glucose tolerance test and 4 more. Started Aug 2022; status: completed.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05463770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05463770.